CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry-Reference-Cited by-同舟云学术

CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry

Published:2018-12 Issue: Volume:158 Page:402-412
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Van Hout Anneleen,Klarenbeek Alex,Bobkov Vladimir,Doijen Jordi,Arimont Marta,Zhao Chunxia,Heukers Raimond^ORCID,Rimkunas Rebecca,de Graaf Chris,Verrips Theo,van der Woning Bas,de Haard Hans,Rucker Joseph B.,Vermeire Kurt,Handel Tracy,Van Loy Tom,Smit Martine J.,Schols Dominique

Funder

KU Leuven

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference58 articles.

1. Chemokines in hematopoiesis;Broxmeyer;Curr. Opin. Hematol.,2008

2. Chemokines in health and disease;Raman;Exp. Cell. Res.,2011

3. Stromal cell-derived factor 1 is secreted by meningeal cells and acts as chemotactic factor on neuronal stem cells of the cerebellar external granular layer;Reiss;Neuroscience,2002

4. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract;Tachibana;Nature,1998

5. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry;Bleul;Nature,1996

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multivalent CXCR4-targeting nanobody formats differently affect affinity, receptor clustering, and antagonism;Biochemical Pharmacology;2024-09

2. Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies;Nature Communications;2024-05-30

3. Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons;World Journal of Microbiology and Biotechnology;2024-05-21

4. CXCR4 Is a Potential Target for Anti-HIV Gene Therapy;International Journal of Molecular Sciences;2024-01-18

5. Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer;Journal of Environmental Pathology, Toxicology and Oncology;2024